nach oben

Erschienen in:

15.04.2021 | Original Article

The longer the antithyroid drug is used, the lower the relapse rate in Graves’ disease: a retrospective multicenter cohort study in Korea

verfasst von: So Young Park, Bo Hyun Kim, Mijin Kim, A.Ram Hong, Jun Park, Hyunju Park, Min Sun Choi, Tae Hyuk Kim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung

Erschienen in: Endocrine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Current literature suggests 12–18 months of antithyroid drug (ATD) treatment for patients with Graves’ disease, but the risk of relapse is high. Although some studies reported better outcomes of long-term ATD treatment, recent data that suggest the optimal treatment duration are limited.

Methods

We performed a multicenter retrospective cohort study of 908 patients newly diagnosed with Graves’ disease between 2006 and 2013. The relapse rate according to ATD treatment duration was analyzed.

Results

After initial ATD treatment, 338 patients (37.2%) had relapsed. The relapse rate according to ATD treatment duration was 42.4% at 1 year, 38.5% at 2 years, 33.8% at 3 years, 31.7% at 4 years, 30.2% at 5 years, 27.8% at 6 years, and 19.1% at more than 6 years, respectively, demonstrating a significant decreasing trend (p = 0.003). In a multivariable Cox regression analysis, ATD treatment duration was an independent risk factor for relapse (p = 0.043).

Conclusions

The longer that ATD therapy is used, the lower the relapse rate is in patients with Graves’ disease. Long-term ATD treatment may be considered in Graves’ patients who do not show complications or an economic burden from hyperthyroidism.

Nur mit Berechtigung zugänglich

I. Klein, D.V. Becker, G.S. Levey, Treatment of hyperthyroid disease. Ann. Intern. Med. 121(4), 281–288 (1994). https://doi.org/10.7326/0003-4819-121-4-199408150-00010CrossRefPubMed

T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58(2), 95–100 (2011). https://doi.org/10.1507/endocrj.k10e-262CrossRefPubMed

D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, M.A. Walter, 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10), 1343–1421 (2016). https://doi.org/10.1089/thy.2016.0229CrossRefPubMed

G.J. Kahaly, L. Bartalena, L. Hegedus, L. Leenhardt, K. Poppe, S.H. Pearce, 2018 European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur. Thyroid J. 7(4), 167–186 (2018). https://doi.org/10.1159/000490384CrossRefPubMedPubMedCentral

P. Abraham, A. Avenell, C.M. Park, W.A. Watson, J.S. Bevan, A systematic review of drug therapy for Graves’ hyperthyroidism. Eur. J. Endocrinol. 153(4), 489–498 (2005). https://doi.org/10.1530/eje.1.01993CrossRefPubMed

P. Abraham, A. Avenell, S.C. McGeoch, L.F. Clark, J.S. Bevan, Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst. Rev. (1), Cd003420 (2010). https://doi.org/10.1002/14651858.CD003420.pub4

F. Azizi, R. Malboosbaf, Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27(10), 1223–1231 (2017). https://doi.org/10.1089/thy.2016.0652CrossRefPubMed

O.E. Okosieme, P.N. Taylor, C. Evans, D. Thayer, A. Chai, I. Khan, M.S. Draman, B. Tennant, J. Geen, A. Sayers, R. French, J.H. Lazarus, L.D. Premawardhana, C.M. Dayan, Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 7(4), 278–287 (2019). https://doi.org/10.1016/s2213-8587(19)30059-2CrossRefPubMed

R.V. Garcia-Mayor, C. Paramo, R. Luna Cano, L.F. Perez Mendez, J.C. Galofre, A. Andrade, Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J. Endocrinol. Investig. 15(11), 815–820 (1992). https://doi.org/10.1007/bf03348811CrossRef

10.

D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J.Y. Herry, H. Allannic, Antithyroid drugs and Graves’ disease-prospective randomized assessment of long-term treatment. Clin. Endocrinol. 50(1), 127–132 (1999). https://doi.org/10.1046/j.1365-2265.1999.00629.xCrossRef

11.

T.J. Smith, L. Hegedus, Graves’ disease. N. Engl. J. Med. 375(16), 1552–1565 (2016). https://doi.org/10.1056/NEJMra1510030CrossRefPubMed

12.

B. Goichot, S. Bouée, C. Castello-Bridoux, P. Caron, Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur. Thyroid J. 6(3), 152–159 (2017). https://doi.org/10.1159/000453260CrossRefPubMedPubMedCentral

13.

R. Negro, R. Attanasio, F. Grimaldi, R. Guglielmi, E. Papini, A 2015 Italian survey of clinical practice patterns in the management of Graves’ disease: comparison with European and North American surveys. Eur. Thyroid J. 5(2), 112–119 (2016). https://doi.org/10.1159/000444482CrossRefPubMedPubMedCentral

14.

E. Mazza, M. Carlini, D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba, S. Beninati, M. Messina, Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol. Investig. 31(10), 866–872 (2008). https://doi.org/10.1007/bf03346433CrossRef

15.

T. Kashiwai, Y. Hidaka, T. Takano, K.I. Tatsumi, Y. Izumi, Y. Shimaoka, H. Tada, K. Takeoka, N. Amino, Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves’ disease. Endocr. J. 50(1), 45–49 (2003). https://doi.org/10.1507/endocrj.50.45CrossRefPubMed

16.

G.H. Seo, S.W. Kim, J.H. Chung, Incidence & prevalence of hyperthyroidism and preference for therapeutic modalities in Korea. J. Korean Thyroid Assoc. 6(1), 5656–63 (2013)CrossRef

17.

K.H. Yi, J.H. Moon, I.-J. Kim, H.-S. Bom, J. Lee, W.Y. Chung, J.H. Chung, Y.K. Shong, The diagnosis and management of hyperthyroidism consensus–report of the Korean Thyroid Association. J. Korean Thyroid Assoc. 6(1), 1–11 (2013)CrossRef

18.

L. Elbers, M. Mourits, W. Wiersinga, Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid 21(3), 279–283 (2011). https://doi.org/10.1089/thy.2010.0181CrossRefPubMed

19.

F. Azizi, M. Takyar, E. Madreseh, A. Amouzegar, Long-term methimazole therapy in Juvenile Graves’ disease: a randomized trial. Pediatrics 143(5) (2019). https://doi.org/10.1542/peds.2018-3034

20.

F. Azizi, A. Amouzegar, M. Tohidi, M. Hedayati, D. Khalili, L. Cheraghi, Y. Mehrabi, M. Takyar, Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid 29(9), 1192–1200 (2019). https://doi.org/10.1089/thy.2019.0180CrossRefPubMed

21.

P. Anagnostis, F. Adamidou, S.A. Polyzos, S. Katergari, E. Karathanasi, C. Zouli, A. Panagiotou, M. Kita, Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 44(2), 448–453 (2013). https://doi.org/10.1007/s12020-013-9895-0CrossRefPubMed

22.

E. Masiello, G. Veronesi, D. Gallo, P. Premoli, E. Bianconi, S. Rosetti, C. Cusini, J. Sabatino, S. Ippolito, E. Piantanida, M.L. Tanda, L. Chiovato, W.M. Wiersinga, L. Bartalena, Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J. Endocrinol. Investig. 41(12), 1425–1432 (2018). https://doi.org/10.1007/s40618-018-0918-9CrossRef

23.

X.G. Vos, E. Endert, A.H. Zwinderman, J.G. Tijssen, W.M. Wiersinga, Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 101(4), 1381–1389 (2016). https://doi.org/10.1210/jc.2015-3644CrossRefPubMed

24.

H. Shi, R. Sheng, Y. Hu, X. Liu, L. Jiang, Z. Wang, D. Cui, Risk factors for the relapse of Graves’ disease treated with antithyroid drugs: a systematic review and meta-analysis. Clin. Ther. 42(4), 662–675.e664 (2020). https://doi.org/10.1016/j.clinthera.2020.01.022CrossRefPubMed

25.

R.V. García-Mayor, P. Álvarez-Vázquez, E. Fluiters, D. Valverde, A. Andrade, Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value. Endocrine 63(2), 316–322 (2019). https://doi.org/10.1007/s12020-018-1785-zCrossRefPubMed

26.

P. Laurberg, Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur. J. Endocrinol. 155(6), 783–786 (2006). https://doi.org/10.1530/eje.1.02295CrossRefPubMed

27.

K.W. Wenzel, J.R. Lente, Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves’ disease: evidence against an immunosuppressive action of thionamide drugs. J. Clin. Endocrinol. Metab. 58(1), 62–69 (1984). https://doi.org/10.1210/jcem-58-1-62CrossRefPubMed

28.

O. Törring, L. Tallstedt, G. Wallin, G. Lundell, J.G. Ljunggren, A. Taube, M. Sääf, B. Hamberger, Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group. J. Clin. Endocrinol. Metab. 81(8), 2986–2993 (1996). https://doi.org/10.1210/jcem.81.8.8768863CrossRefPubMed

29.

S. Côté-Bigras, V. Tran, S. Turcotte, M. Rola-Pleszczynski, J. Verreault, D. Rottembourg, Impaired immune regulation after radioiodine therapy for Graves’ disease and the protective effect of Methimazole. Endocrine 52(3), 587–596 (2016). https://doi.org/10.1007/s12020-015-0832-2CrossRefPubMed

30.

R.S. Rittmaster, E.C. Abbott, R. Douglas, M.L. Givner, L. Lehmann, S. Reddy, S.R. Salisbury, A.H. Shlossberg, M.H. Tan, S.E. York, Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease. J. Clin. Endocrinol. Metab. 83(3), 814–818 (1998). https://doi.org/10.1210/jcem.83.3.4613CrossRefPubMed

31.

I. Kruljac, D. Solter, A.M. Vrkljan, M. Solter, Remission of Graves’ disease is not related to early restoration of euthyroidism with high-dose methimazole therapy. Endocr. Res. 40(1), 25–28 (2015). https://doi.org/10.3109/07435800.2014.914038CrossRefPubMed

32.

P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, O. Tørring, TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur. J. Endocrinol. 158(1), 69–75 (2008). https://doi.org/10.1530/eje-07-0450CrossRefPubMed

33.

S. Kautbally, O. Alexopoulou, C. Daumerie, F. Jamar, M. Mourad, D. Maiter, Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves’ disease previously treated with antithyroid drugs. Eur. Thyroid J. 1(2), 122–128 (2012). https://doi.org/10.1159/000339473CrossRefPubMedPubMedCentral

34.

Y.J. Chung, B.W. Lee, J.Y. Kim, J.H. Jung, Y.K. Min, M.S. Lee, M.K. Lee, K.W. Kim, J.H. Chung, Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves’ patients. Thyroid 16(12), 1251–1257 (2006). https://doi.org/10.1089/thy.2006.16.1251CrossRefPubMed

35.

R. Volpé, The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr. Pharm. Des. 7(6), 451–460 (2001). https://doi.org/10.2174/1381612013397898CrossRefPubMed

36.

F. Azizi, R. Malboosbaf, Safety of long-term antithyroid drug treatment? A systematic review. J. Endocrinol. Investig. 42(11), 1273–1283 (2019). https://doi.org/10.1007/s40618-019-01054-1CrossRef

37.

C.M. Riguetto, A.M. Neto, M.A. Tambascia, D.E. Zantut-Wittmann, The relationship between quality of life, cognition, and thyroid status in Graves’ disease. Endocrine 63(1), 87–93 (2019). https://doi.org/10.1007/s12020-018-1733-yCrossRefPubMed

38.

P. Miccoli, M.N. Minuto, R. Paggini, P. Rucci, A. Oppo, G. Donatini, F. Golia, L. Novelli, M. Carlini, L. Dell’Osso, The impact of thyroidectomy on psychiatric symptoms and quality of life. J. Endocrinol. Investig. 30(10), 853–859 (2007). https://doi.org/10.1007/bf03349227CrossRef

39.

K.W. Choi, Y. Kim, M. Fava, D. Mischoulon, E.J. Na, S.W. Kim, M.H. Shin, M.K. Chung, H.J. Jeon, Increased morbidity of major depressive disorder after thyroidectomy: a nationwide population-based study in South Korea. Thyroid 29(12), 1713–1722 (2019). https://doi.org/10.1089/thy.2019.0091CrossRefPubMed

40.

E. Stokhuijzen, A.F. van der Steeg, E.J. Nieveen van Dijkum, H.M. van Santen, A.S. van Trotsenburg, Quality of life and clinical outcome after thyroid surgery in children: a 13 years single center experience. J. Pediatr. Surg. 50(10), 1701–1706 (2015). https://doi.org/10.1016/j.jpedsurg.2015.02.067CrossRefPubMed

41.

H.B. Burch, K.D. Burman, D.S. Cooper, A 2011 survey of clinical practice patterns in the management of Graves’ disease. J. Clin. Endocrinol. Metab. 97(12), 4549–4558 (2012). https://doi.org/10.1210/jc.2012-2802CrossRefPubMed

Titel: The longer the antithyroid drug is used, the lower the relapse rate in Graves’ disease: a retrospective multicenter cohort study in Korea
verfasst von: So Young Park
Bo Hyun Kim
Mijin Kim
A.Ram Hong
Jun Park
Hyunju Park
Min Sun Choi
Tae Hyuk Kim
Sun Wook Kim
Ho-Cheol Kang
Jae Hoon Chung
Publikationsdatum: 15.04.2021
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02725-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The longer the antithyroid drug is used, the lower the relapse rate in Graves’ disease: a retrospective multicenter cohort study in Korea